Inovio Pharmaceuticals is a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company has developed antigen-targeting immunotherapy and vaccine product candidates for HPV-caused precancers and cancers, breast, lung, pancreatic, and prostate cancer, hepatitis, HIV, influenza, Ebola, and other diseases. Inovio was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.